Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study) (Q82693275)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 December 2011

Language	Label	Description	Also known as
English	Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study)	scientific article published on 01 December 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

Efficacy and Safety of Tolvaptan in Heart Failure Patients with Volume Overload Despite the Standard Treatment with Conventional Diuretics: A Phase III, Randomized, Double-blind, Placebo-controlled Study (QUEST Study) (English)

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

antidiuretic hormone receptor antagonists

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:22120092

18 December 2024

author name string

Masunori Matsuzaki

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

Masatsugu Hori

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

Tohru Izumi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

Masatake Fukunami

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

Tolvaptan Investigators

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22120092

18 December 2024

publication date

1 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

December 2011

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22120092

18 December 2024

full work available at URL

http://link.springer.com/content/pdf/10.1007/s10557-011-6304-x.pdf

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

http://link.springer.com/article/10.1007/s10557-011-6304-x/fulltext.html

HyperText Markup Language

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

http://link.springer.com/content/pdf/10.1007/s10557-011-6304-x

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Cardiovascular Drugs and Therapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

25 Suppl 1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

S33-45

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure

2

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

3

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Diuretic usage in heart failure: a continuing conundrum in 2005.

4

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Haemodynamic effects of diuretics in heart failure

5

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group

6

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction

7

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

9

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure

10

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Effects of Tolvaptan on Volume Overload in Japanese Patients with Heart Failure: Results of a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study

11

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Piretanide: a loop-active diuretic. Pharmacology, therapeutic efficacy and adverse effects

12

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

13

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

15

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials

16

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Efficacy and Safety of Tolvaptan in Heart Failure Patients with Sustained Volume Overload despite the Use of Conventional Diuretics: A Phase III Open-Label Study

17

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Phase III Clinical Pharmacology Study of Tolvaptan

18

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction

19

1 reference

10.1007/S10557-011-6304-X

https://api.crossref.org/works/10.1007/S10557-011-6304-X

18 December 2024

Identifiers

10.1007/S10557-011-6304-X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22120092 AND SRC:MED&resulttype=core&format=json

17 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q82693275&oldid=2289180858"